HT 6258
Alternative Names: HT-6258Latest Information Update: 02 Jan 2024
At a glance
- Originator Halia Therapeutics
- Class Small molecules
- Mechanism of Action NEK7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders
Most Recent Events
- 19 Dec 2023 Preclinical trials in Gastrointestinal disorders in USA (unspecified route) prior to December 2023 (Halia Therapeutics pipeline, December 2023)
- 18 Dec 2023 Halia Therapeutics plans to file an IND application with the regulatory body for Gastrointestinal disorders in 2024 (Halia Therapeutics pipeline, December 2023)